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Abstract
I In nt tr ro od du uc ct ti io on n: :   Two functional single nucleotide polymorphisms (SNPs) in the 
5,10-methylenetetrahydrofolate reductase (MTHFR) gene, C677T and A1298C,
lead to decreased enzyme activity and affect chemosensitivity of tumour cells. 
M Ma at te er ri ia al l   a an nd d   m me et th ho od ds s: :   We evaluated these two common polymorphisms and
breast cancer risk association in an Iranian sporadic breast cancer population-
based case-control study of 294 breast cancer cases and 306 controls using
a PCR-RFLP-based assay.
R Re es su ul lt ts s: :   Analyses of affected and controls show that homozygote genotype
MTHFR 677CC has the highest frequency in both groups (28.3% in patients and
25.3% in control group). Genotype MTHFR 677CT and genotype MTHFR 1298AC
were found to be statistically significant risk factors in our population (odds
ratio: 1.6, 95% CI: 1.019-2.513, p = 0.041; and odds ratio: 2.575, 95% CI: 1.590-
4.158, p = 0.001 respectively).
C Co on nc cl lu us si io on ns s: :   We can conclude based on the results of our study that a significant
association between breast cancer and C677T and A1298C polymorphism might
exist.
K Ke ey y   w wo or rd ds s: :   MTHFR gene, polymorphism, breast cancer, PCR-RFLP, susceptibility
factor.
Introduction
MTHFR is a key enzyme in the folate metabolism pathway and regulates
the intracellular folate pool for synthesis and methylation of DNA [1, 2].
Two common allele variants of the MTHFR gene have been described,
C677T and A1298C, that lead to amino acid substitutions, Ala222Val and
Glu429Ala, and to decreased enzyme activity [3-5].
Folate is involved in DNA methylation, synthesis, and repair. Low intake of
folate may increase the risk of several cancers, including breast cancer [5, 6].
The enzyme methylenetetrahydrofolate reductase (MTHFR) irreversibly
catalyzes 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, the
donor for the remethylation of homocysteine to methionine, the precursor
for the universal methyl donor S-adenosylmethionine [7, 8]. Two common
polymorphisms in the MTHFR gene have been characterized [9, 10]: the
677C ₒ T [9, 11] and the 1298A ₒ C polymorphism codes [10]. Individuals
homozygous for the 1298C allele have approximately the same enzyme
activity as those heterozygous for the 677T allele [10, 11]. 
We report here that the allele frequencies of MTHFR 677 and 1298 were
significant in breast cancer patients in Iran.
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Material and methods
P Pa at ti ie en nt t   d da at ta a
Studies  were  conducted  on  294  carcinoma
breast cancer patients treated with chemotherapy
and  306  controls  comprising  postmenopausal
women genotyped for MTHFR, aged 45-55 years.
All patients were from the chemotherapy ward
in the Special Medical Centre, Tehran, Iran. 
This study was ethically approved by the local
Ethical Committee of Islamic Azad University from
the point of view of patients’ and controls’ rights. 
A questionnaire and a consent form including
questions  on  breast  cancer  risk  factors  were
completed by each patient. The blood samples were
collected from patients and controls prior to the
start of treatment. Subjects were genotyped for
MTHFR SNPS using genomic DNA extracted from
peripheral blood lymphocytes. DNA was isolated
from  peripheral  blood  using  a FlexiGene  DNA
extraction kit (Qiagen Germany). 
G Ge en no ot ty yp pi in ng g
The  polymorphisms  were  detected  using
a modified PCR-RFLP method [12, 13, 16]. The PCR
primers were synthesized by TAG Copenhagen A/S
Primers which were: 
1)  A1298C polymorphism (256 bp), 
forward: 5’-CTTCTACCTGAAGAGCAAGTC-3’,
reverse: 5’-CATGTCCACAGCATGGAG-3’.
The cycling conditions were 94°C, 30 min; 61°C,
30 min (35 cycles); 72°C, 60 min. The PCR products
were digested with 1 unit of MboII (Figure 1).
2) C677T (183 bp), 
forward primer: GACCTGAAGCACTTGAAGGA,
reverse primer: CGAGCTTATGGGCTCTCCTG. 
The cycling conditions were 94°C, 30 min; 61°C,
30 min (35 cycles); 72°C, 60 min. The PCR products
were digested with 1 unit of HinfI, and separated
on a 4% agarose gel (Figure 2).
This method is able to detect all three possible
genotypes for the polymorphism: homozygous wild
type, heterozygous variant type and homozygous
variant type.
The genotypes and allelic frequencies of MTHFR
polymorphisms in patient and control groups were
analysed by ˇ2 and Fisher’s exact tests. P values 
< 0.05 were considered significant. 
Results
There was a significant result for MTHFR 1298
and 677 polymorphism in relation to breast cancer
risk. Analyses of affected and controls show that
homozygote  genotype  MTHFR  677CC  has  the
highest frequency in both groups (28.3% in patients
and 25.3% in control group), p = 0.001. 
On the other hand, the homozygous genotype
MTHFR 1298 CC was more increased in the patient
group (27.3%) compared with controls (17.7%), 
p = 0.001 (Tables I, II and Figure 3).
The  genotype  MTHFR  677CT  and  genotype
MTHFR 1298AC were found or appeared to be
important risk factors in our population (odds ratio:
1.6, 95% CI: 1.019-2.513, p = 0.041; and odds ratio:
2.575, 95% CI: 1.590-4.158, p = 0.001 respectively),
while MTHFR 677 CC did not show any statistical
significance (odds ratio: 1.2, p = 0.334).
Of course, MTHFR 1298 CC (27.3%) and MTHFR
677 CC (28.3%) have the highest frequency com  -
pared with MTHFR 677 and MTHFR 1298 poly  -
morphism. 
In our study there was an association between
C677T  and  A1298C  polymorphism  and  breast
cancer risk.
We conclude that not only was 1298 CC asso  -
ciated with increased risk for breast cancer but also
there  is  a relation  between  the  presence  of 
677 CC and increased breast cancer risk.
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F Fi ig gu ur re e   1 1. .   Polymorphism analysis of MTHFR 1298. 
The PCR products were digested with restriction
enzyme MboII in groups: 1,2; CA genotype (256 bp,
176 bp, 52 bp, 30, 28, 22 bp), 5,6 CC genotype (176,
52, 30, 28, 22 bp), 4,7; AA genotype (256 bp), 3;
negative control, 8; (ladder 50 bp)
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F Fi ig gu ur re e   2 2. .   Polymorphism analysis of MTHFR 677. 
The PCR products were digested with restriction
enzyme Hinf I in groups: 1,12,13; CT genotype (183 bp,
153 bp, 35 bp), 2,3,4,5,7,9,10,11,14 CC genotype 
(183 bp) 6; TT genotype (153 bp, 35 bp), 8; negative
control, 15; (ladder 50 bp)
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Discussion
Martin DN [14] found that the MTHFR SNPs
C677T and A1298C were associated with breast
cancer survival. 
Jakubowska found that MTHFR_677_C > T was
associated with an increased risk while 1298_A > C
polymorphism was associated with a decreased risk
for breast and ovarian cancer. It appears that
functional  polymorphisms  in  the  MTHFR gene
modify the risk of breast cancer and may potentially
alter the risk of ovarian cancer in women with an
inherited predisposition [15].
Shrubsole MJ did not observe any effect of
A1298C  genotypes  on  breast  cancer  risk.  He
suggests that the MTHFR C677T polymorphisms
may modify the association between dietary folate
intake and breast cancer risk [16, 17].
However, other studies on colorectal cancer [18],
colorectal adenoma [19-21], gastric cancer [22], lung
cancer [23], and acute myeloid leukaemia [24] did
not find any association or an increased risk of
cancer for individuals with the TT genotype. 
The C677T polymorphism has been examined in
relation to several cancers [6, 22]. Many studies
have also examined the correlation between MTHFR
677TT and breast cancer risk [18–20, 25-28]. 
In the first study in Jewish women, there was no
significant difference of MTHFR C677T genotype
between sporadic cases and controls [26]. 
In Caucasian women it was reported that the
MTHFR 677T allele was more prevalent in cases
than  controls  [27],  while  in  other  studies  the
reported risk for breast cancer was associated with
both the C677T and A1298C polymorphisms [28].
In our study, a statistically significant association
between MTHFR genotype and breast cancer risk
was found. Therefore, we can conclude that there
might be a relation between the presence of MTHFR
1298AA and 677CC genotype and increasing risk of
breast cancer, whereas there was a decreased
frequency for MTHFR 677 CT, TT and 1298 CT, AA
compared with controls.
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G Ge en no ot ty yp pe e O Od dd ds s   r ra at ti io o 9 95 5% %   c co on nf fi id de en nc ce e    P P v va al lu ue e
M MT TH HF FR R ( (1 12 29 98 8) ) i in nt te er rv va al l
AC 2.571 1.590-4.158 0.001***
CC 2.170 1.515-3.106 0.002***
AA 1.185 0.727-1.933 0.496
G Ge en no ot ty yp pe e
M MT TH HF FR R ( (6 67 77 7) )
CC 1.2 0.829-1.737 0.334
CT 1.6 1.019-2.513 0.041
TT 1.333 0.814-2.185 0.253
T Ta ab bl le e   I II I. .   Comparison between genotypes, odds ratio
and p value showed that p value of genotype MTHFR
677 CT was the most important risk factor in our
population; TC odds ratio, 1.6 (95% confidence inter  -
val; CI, 1.019-2.513), p = 0.041, CC odds ratio, 1.2 
(95% CI, 0.829-1.737), p = 0.334, TT odds ratio, 1.333
(95% CI, 0.814-2.185), p = 0.253. Genotype MTHFR
1298 AC was the most important risk factor in our
population; AC odds ratio, 2.571 (95% confidence
interval; CI, 1.590-4.158), p = 0.001, AA odds ratio,
1.185 (95% CI, 0.727-1.933), p = 0.496, CC odds ratio,
2.170 (95% CI, 1.515-3.106), p = 0.002
G Ge en no ot ty yp pe e P Pa at ti ie en nt ts s    C Co on nt tr ro ol ls s T To ot ta al l
n n ( (% %) ) n n ( (% %) ) n n   ( (% %) )
n 294 306 600
M MT TH HF FR R   ( (6 67 77 7) )
CC 168 (28.3) 150 (25.3) 318 (53.5)
CT 84 (14.1) 90 (15.2) 174 (29.3)
TT 42 (7.1) 60 (10.1) 102 (17.2)
M MT TH HF FR R ( (1 12 29 98 8) )
CC 162 (27.3) 105 (17.7) 267 (44.9)
AC 96 (16.2) 135 (22.7) 231 (38.9)
AA 36 (6.1) 60 (10.1) 96 (16.2)
T Ta ab bl le e   I I. .   MTHFR 677 and 1298 genotype frequencies
[n (%)] for patients and controls: Analyses of 294
affected women and 306 controls show the highest
frequency for C/C MTHFR 677 genotype (28.3 and
25.3 respectively) and C/C MTHFR 1298 genotype
(27.3 and 17.7 respectively)
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F Fi ig gu ur re e    3 3. .    MTHFR  677  and  1298  genotype  (X)
frequencies (Y) [n (%)] for cases and controls: Ana  -
lyses of 294 affected women and 306 controls
showed the highest frequency for C/C MTHFR 677
genotype (28.3 and 25.3 respectively) and C/C MTHFR
1298 genotype (27.3 and 17.7 respectively). On the
other hand, a decreased frequency of MTHFR 677
CT, TT and 1298 CT, AA was found for patients com  -
pared to controls 
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